Emmaus Life Sciences Stock Performance
| EMMA Stock | USD 0.01 0.0001 0.71% |
Emmaus Life holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -2.47, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Emmaus Life are expected to decrease by larger amounts. On the other hand, during market turmoil, Emmaus Life is expected to outperform it. Use Emmaus Life downside variance, day median price, and the relationship between the maximum drawdown and skewness , to analyze future returns on Emmaus Life.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Emmaus Life Sciences are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady primary indicators, Emmaus Life sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.5 M | |
| Total Cashflows From Investing Activities | -6.4 M |
Emmaus |
Emmaus Life Relative Risk vs. Return Landscape
If you would invest 0.93 in Emmaus Life Sciences on November 4, 2025 and sell it today you would earn a total of 0.46 from holding Emmaus Life Sciences or generate 49.46% return on investment over 90 days. Emmaus Life Sciences is currently generating 1.0731% in daily expected returns and assumes 9.7182% risk (volatility on return distribution) over the 90 days horizon. In different words, 87% of otc stocks are less volatile than Emmaus, and 79% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Emmaus Life Target Price Odds to finish over Current Price
The tendency of Emmaus OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.01 | 90 days | 0.01 | about 8.92 |
Based on a normal probability distribution, the odds of Emmaus Life to move above the current price in 90 days from now is about 8.92 (This Emmaus Life Sciences probability density function shows the probability of Emmaus OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Emmaus Life Sciences has a beta of -2.47 suggesting as returns on its benchmark rise, returns on holding Emmaus Life Sciences are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Emmaus Life is expected to outperform its benchmark. Additionally Emmaus Life Sciences has an alpha of 0.9967, implying that it can generate a 1.0 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Emmaus Life Price Density |
| Price |
Predictive Modules for Emmaus Life
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Emmaus Life Sciences. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Emmaus Life Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Emmaus Life is not an exception. The market had few large corrections towards the Emmaus Life's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Emmaus Life Sciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Emmaus Life within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.00 | |
β | Beta against Dow Jones | -2.47 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.09 |
Emmaus Life Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Emmaus Life for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Emmaus Life Sciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Emmaus Life Sciences is way too risky over 90 days horizon | |
| Emmaus Life Sciences has some characteristics of a very speculative penny stock | |
| Emmaus Life Sciences appears to be risky and price may revert if volatility continues | |
| Emmaus Life Sciences currently holds 4.65 M in liabilities. Emmaus Life Sciences has a current ratio of 0.14, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Emmaus Life until it has trouble settling it off, either with new capital or with free cash flow. So, Emmaus Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Emmaus Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Emmaus to invest in growth at high rates of return. When we think about Emmaus Life's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 20.61 M. Net Loss for the year was (15.95 M) with profit before overhead, payroll, taxes, and interest of 17.3 M. | |
| Emmaus Life Sciences currently holds about 982 K in cash with (1.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 39.0% of the company shares are held by company insiders | |
| Latest headline from seekingalpha.com: Alcoa downgraded at Morgan Stanley after strong YTD performance |
Emmaus Life Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Emmaus OTC Stock often depends not only on the future outlook of the current and potential Emmaus Life's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Emmaus Life's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 49.3 M | |
| Cash And Short Term Investments | 2.3 M |
Emmaus Life Fundamentals Growth
Emmaus OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Emmaus Life, and Emmaus Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Emmaus OTC Stock performance.
| Return On Asset | -0.12 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (0.65) % | |||
| Current Valuation | 49.41 M | |||
| Shares Outstanding | 49.56 M | |||
| Price To Earning | (1.60) X | |||
| Price To Sales | 1.06 X | |||
| Revenue | 20.61 M | |||
| EBITDA | (12.76 M) | |||
| Cash And Equivalents | 982 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 4.65 M | |||
| Debt To Equity | (0.04) % | |||
| Book Value Per Share | (0.76) X | |||
| Cash Flow From Operations | (1.25 M) | |||
| Earnings Per Share | (0.18) X | |||
| Total Asset | 56.73 M | |||
| Retained Earnings | (82.78 M) | |||
| Current Asset | 9.19 M | |||
| Current Liabilities | 7.25 M | |||
About Emmaus Life Performance
By analyzing Emmaus Life's fundamental ratios, stakeholders can gain valuable insights into Emmaus Life's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Emmaus Life has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Emmaus Life has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California. Emmaus Life operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 58 people.Things to note about Emmaus Life Sciences performance evaluation
Checking the ongoing alerts about Emmaus Life for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Emmaus Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Emmaus Life Sciences is way too risky over 90 days horizon | |
| Emmaus Life Sciences has some characteristics of a very speculative penny stock | |
| Emmaus Life Sciences appears to be risky and price may revert if volatility continues | |
| Emmaus Life Sciences currently holds 4.65 M in liabilities. Emmaus Life Sciences has a current ratio of 0.14, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Emmaus Life until it has trouble settling it off, either with new capital or with free cash flow. So, Emmaus Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Emmaus Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Emmaus to invest in growth at high rates of return. When we think about Emmaus Life's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 20.61 M. Net Loss for the year was (15.95 M) with profit before overhead, payroll, taxes, and interest of 17.3 M. | |
| Emmaus Life Sciences currently holds about 982 K in cash with (1.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 39.0% of the company shares are held by company insiders | |
| Latest headline from seekingalpha.com: Alcoa downgraded at Morgan Stanley after strong YTD performance |
- Analyzing Emmaus Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Emmaus Life's stock is overvalued or undervalued compared to its peers.
- Examining Emmaus Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Emmaus Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Emmaus Life's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Emmaus Life's otc stock. These opinions can provide insight into Emmaus Life's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Emmaus OTC Stock analysis
When running Emmaus Life's price analysis, check to measure Emmaus Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emmaus Life is operating at the current time. Most of Emmaus Life's value examination focuses on studying past and present price action to predict the probability of Emmaus Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emmaus Life's price. Additionally, you may evaluate how the addition of Emmaus Life to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |